These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 26690657)

  • 41. Strategies of radioiodine ablation in patients with low-risk thyroid cancer.
    Schlumberger M; Catargi B; Borget I; Deandreis D; Zerdoud S; Bridji B; Bardet S; Leenhardt L; Bastie D; Schvartz C; Vera P; Morel O; Benisvy D; Bournaud C; Bonichon F; Dejax C; Toubert ME; Leboulleux S; Ricard M; Benhamou E;
    N Engl J Med; 2012 May; 366(18):1663-73. PubMed ID: 22551127
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Thyroid suppression and radioiodine treatment for differentiated thyroid cancer.
    Rösler H
    Arch Otolaryngol Head Neck Surg; 1987 Jul; 113(7):778-9. PubMed ID: 3580165
    [No Abstract]   [Full Text] [Related]  

  • 43. Signaling Pathways in Thyroid Cancer.
    Jin S; Yang YT; Bao W
    Vitam Horm; 2018; 106():501-515. PubMed ID: 29407446
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of 131I in the treatment of well differentiated thyroid cancer.
    Woodrum DT; Gauger PG
    J Surg Oncol; 2005 Mar; 89(3):114-21. PubMed ID: 15719384
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
    Jarzab B; Handkiewicz-Junak D; Wloch J
    Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Update on recent developments in the therapy of differentiated thyroid cancer.
    Middendorp M; Grünwald F
    Semin Nucl Med; 2010 Mar; 40(2):145-52. PubMed ID: 20113682
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients.
    Gruber JJ; Colevas AD
    Oncologist; 2015 Feb; 20(2):113-26. PubMed ID: 25616432
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeted therapy for thyroid cancer: An updated review of investigational agents.
    Deshpande HA; Gettinger SN; Sosa JA
    Curr Opin Investig Drugs; 2010 Jun; 11(6):661-8. PubMed ID: 20496261
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma.
    Yeung KT; Cohen EE
    Clin Cancer Res; 2015 Dec; 21(24):5420-6. PubMed ID: 26487760
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Conventional withdrawal of thyroid hormone before radioiodine therapy in differentiated thyroid carcinoma: how frequently are adequately raised TSH levels attained?
    McLaughlin CM; Hunter SJ; Bell PM; McCance DR; Sheridan B; Atkinson AB
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):169-70. PubMed ID: 18042175
    [No Abstract]   [Full Text] [Related]  

  • 51. Multitargeted Kinase Inhibition in Metastatic Differentiated Radioiodine-Refractory Thyroid Cancer: A Look at New Therapeutic Options for a Rare Disease.
    Mischler K; Kneifel S; Cathomas R
    Oncol Res Treat; 2016; 39(9):548-52. PubMed ID: 27614988
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.
    Woyach JA; Kloos RT; Ringel MD; Arbogast D; Collamore M; Zwiebel JA; Grever M; Villalona-Calero M; Shah MH
    J Clin Endocrinol Metab; 2009 Jan; 94(1):164-70. PubMed ID: 18854394
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Redifferentiation therapy in advanced thyroid cancer.
    Haugen BR
    Curr Drug Targets Immune Endocr Metabol Disord; 2004 Sep; 4(3):175-80. PubMed ID: 15379720
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recombinant humane thyrotropin (rhtSH) a new aid in the diagnosis and treatment of thyroid carcinoma with radio-iodine.
    Brans B; Gemmel F; De Winter O; Fiers T; De Roose J; Vermeersch H; Rubens R; Kaufman JM; Dierckx RA
    Acta Clin Belg; 2001; 56(5):316-20. PubMed ID: 11770226
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Age of menopause in patients with differentiated thyroid cancer treated with radioiodine].
    Manuel García-Quirós Muñoz J; Martín Hernández T; Torres Cuadro A; Cambil Molina T; Castro Montaño J; Sendón Pérez A
    Endocrinol Nutr; 2010 Mar; 57(3):105-9. PubMed ID: 20304710
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
    Gallo M; Michelon F; Castiglione A; Felicetti F; Viansone AA; Nervo A; Zichi C; Ciccone G; Piovesan A; Arvat E
    Endocrine; 2015 Aug; 49(3):726-34. PubMed ID: 25414068
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular targeted therapies for patients with refractory thyroid cancer.
    Chougnet C; Brassard M; Leboulleux S; Baudin E; Schlumberger M
    Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):448-55. PubMed ID: 20554167
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An orally available inverse agonist of estrogen-related receptor gamma showed expanded efficacy for the radioiodine therapy of poorly differentiated thyroid cancer.
    Kim J; Hwang H; Yoon H; Lee JE; Oh JM; An H; Ji HD; Lee S; Cha E; Ma MJ; Kim DS; Lee SJ; Kadayat TM; Song J; Lee SW; Jeon JH; Park KG; Lee IK; Jeon YH; Chin J; Cho SJ
    Eur J Med Chem; 2020 Nov; 205():112501. PubMed ID: 32758860
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Thyrotropin in the development and management of differentiated thyroid cancer.
    McLeod DS
    Endocrinol Metab Clin North Am; 2014 Jun; 43(2):367-83. PubMed ID: 24891167
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Approach to the patient with advanced differentiated thyroid cancer.
    Schlumberger M; Sherman SI
    Eur J Endocrinol; 2012 Jan; 166(1):5-11. PubMed ID: 21890651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.